Project Grant R56HL163607
Award Date
9/1/23
Completion Date
8/31/24
Dollars Obligated
$501K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Athens, GA 30602, USA
Similar Awards
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $1,061,189 to the Regents of the University of Michigan to conduct research on the mechanisms underlying lung injury, fibrosis, and susceptibility to bacterial infections. The key objectives are to study: 1) how epithelial cell signaling regulates fibrosis and interacts with myeloid cells, 2) the impaired innate immunity against...
The University of North Carolina at Chapel Hill (UNC-CH) received a $759,983 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research (CFDA 93.837) program. The award supports research examining the mechanisms underlying the diverse responses of neutrophils during Streptococcus pneumoniae pneumonia and acute lung injury. The project aims to determine the changes that neutrophils undergo as they are recruited and perform their...
This $342,900 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to define the functional role of lung microfold (M) cells in predisposition to influenza-associated pneumococcal invasion and resulting pneumonia and sepsis. The research aims to identify the intracellular trafficking mechanisms during pneumococcal transcytosis across airway M cells. The work will be conducted at the...
This $759,025 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) aims to uncover and understand the diverse functions of the protein ICAM-1 in the lungs during homeostasis and innate immune responses. The key objectives are to: 1) determine the functions of soluble ICAM-1 in the alveolar space and its therapeutic potential, 2) examine the roles of ICAM-1 on alveolar epithelial cells in trafficking,...
The University of Tennessee Health Science Center received a $615,455 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research (CFDA 93.837) program. The award, effective September 1, 2024 through June 30, 2028, supports research to investigate the role of eosinophils in promoting antibacterial immunity against Streptococcus pneumoniae, a leading cause of bacterial pneumonia that often co-occurs with influenza infections. The...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), is providing $551,863 to The University of Iowa to define the mechanism by which prostaglandin E2 (PGE2) balances absorption and secretion of airway surface liquid in the lungs. The research aims to establish new regulatory nodes between ion transport, its regulation, and physiological function, with the goal of identifying novel...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $880,735 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Washington. The funding supports research to investigate how cell lysis and release of leukotrienes activate type-2 immunity in the lung. Key objectives include identifying alveolar macrophages as a source of leukotriene C4, examining the roles of leukotrienes in regulating innate lymphoid cell function and downstream...
This $1,504,820 Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) is focused on analyzing the immunologic mechanisms in patients with chronic lung disease after acute COVID-19 infection. The primary objectives are to: Obtain bronchoalveolar lavage (BAL) and peripheral blood samples from patients with persistent lung disease post-COVID for detailed cellular and inflammatory analyses. Further characterize the BAL cellular and...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $695,403 project grant under the Cardiovascular Diseases Research (CFDA 93.837) program to the University of Arizona to conduct research aimed at developing new therapeutic approaches to inhibit the progression of pulmonary fibrosis. The key objectives of the 4-year project are to: Determine whether restoring microvascular integrity through nanoparticle gene therapy can inhibit lung fibrogenesis. Define whether transplantation of...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $684,814 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Regents of the University of California, San Francisco (UCSF) to conduct research on the suppression of alveolar stem cells by tissue-resident lymphocytes in emphysema. The research aims to investigate how lung stromal factors modify the inflammatory response to viral infections and tobacco smoke, and how tissue-resident lymphocytes can...